Enlarge-Lung: Two-Year Follow-Up Of Real-World Patients With Locally Advanced Or Metastatic (Stage Iiib/Iv) Squamous And Non-Squamous Non-Small Cell Lung Cancer (Nsclc) From A National, Prospective, Non-Interventional Study (Nis Enlarge) Of Nivolumab After Prior Chemotherapy In Germany
ONCOLOGY RESEARCH AND TREATMENT(2020)
摘要
Purpose: In two registrational trials, nivolumab showed overall survival (OS) benefit versus docetaxel in pretreated locally advanced or metastatic NSCLC. These results have been confirmed by initial data disclosure of the German NIS ENLARGE. Here we report mature OS data from the first 300 patients enrolled in the trial.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要